Wells Fargo & Company Sio Gene Therapies Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.28 - $0.44 $563 - $884	2,011 Added 555.52%	2,373 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.28 - $0.41 $0 - $0	2 Added 0.56%	362 $0
Q2 2022 Aug 12, 2022	BUY	$0.25 - $0.73 $5 - $16	23 Added 6.82%	360 $0
Q1 2022 May 16, 2022	BUY	$0.55 - $1.47 $1 - $2	2 Added 0.6%	337 $0
Q4 2021 Feb 14, 2022	SELL	$1.29 - $2.36 $641 - $1,172	-497 Reduced 59.74%	335 $0
Q3 2021 Nov 15, 2021	BUY	$1.81 - $2.7 $132 - $197	73 Added 9.62%	832 $2,000
Q2 2021 Aug 16, 2021	BUY	$2.07 - $2.89 $523 - $731	253 Added 50.0%	759 $2,000
Q1 2021 May 13, 2021	SELL	$2.34 - $3.44 $83,325 - $122,494	-35,609 Reduced 98.6%	506 $1,000
Q4 2020 Feb 09, 2021	BUY	$1.91 - $5.63 $68,979 - $203,327	36,115 New	36,115 $100,000

147K

Ticker SIOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,975,200
Description
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.